Background: A number of reports have described the protective effects of ginsenoside Rg1 (Rg1) in Alzheimer's disease (AD). However, the protective mechanisms of Rg1 in AD remain elusive.
Introduction
Alzheimer's disease (AD) is the most common neurodegenerative disorder, usually occurring in people older than 65 years [1] . AD is pathologically characterized by brain shrinkage, amyloid-rich senile plaques, and neurofibrillary tangles [2] . The clinical symptoms of AD are loss of memory, poor recognition ability, changes in personal character, and loss of body control [3, 4] . It has been reported that the main cause of AD is the accumulation of b-amyloid peptides (Ab) [5] . The Ab is produced from the amyloid precursor protein, which is cleaved by b-secretase and g-secretase [6] . The cleaved Ab gives rise to oligomeric forms, which form plaques in the brain [7] . The plaque formations trigger the pathological cascade in AD [4] . Ab 25e35, a very short fragment of Ab, exhibits large b-sheet fibrils and retains the toxicity of the full-length peptides. Thus, Ab 25e35 represents the biologically active region of Ab [8] . It has been reported that Ab 25e35 leads to mitochondrial dysfunctions by blocking the entrance of nuclear-encoded proteins into mitochondria, which diminishes the mitochondrial membrane potential and alters mitochondrial morphology [9] .
Ginseng has been a popular and widely used traditional herbal medicine in Asia for thousands of years. Previous studies have suggested that the components of ginseng exert beneficial effects on neurodegenerative diseases [10] . Ginseng suppresses oxidative stress, regulates apoptotic genes, and inhibits the toxicity of excitatory amino acids [11, 12] . Ginseng is classified into two groups: American ginseng and Asian ginseng. More than 38 ginsenosides, which are known as the major biologically active components, have been identified in Asian ginseng, and one of the major bioactive components is the ginsenoside Rg1 (Rg1) [13] . A number of studies have demonstrated the neuroprotective effects of Rg1 in neurodegenerative disorders such as AD [14] . It has been reported that bsecretase activity and Ab-induced cytotoxicity is inhibited by Rg1 [15] . Although numerous studies have been conducted to assess the neuroprotective effects of Rg1, the protective mechanisms of Rg1 in AD remain elusive.
In the present study, we investigated the protective effects of Rg1 on SH-SY5Y cell damage induced by Ab 25e35 . We performed an MS-based proteomic experiment using stable isotope labeling with amino acids in cell culture (SILAC) to explore the differential proteome expression associated with the protective effects of Rg1 in Ab-treated neuronal cells. Our data may elucidate the neuroprotective molecular mechanism of Rg1 in AD.
Materials and methods

Ab 25e35 aggregation
Ab 25e35 (AnaSpec, Fremont, CA, USA) was dissolved in distilled water at a concentration of 2.5 mM and the solutions was incubated at 37 C for one week before use [16, 17] .
SILAC
SILAC was performed as previously reported [18] . Briefly, SH-SY5Y cells were cultured for at least five cell divisions in either light SILAC medium containing 
In-gel digestion
Each gel was cut into 10 bands of equal size, de-stained with 50% acetonitrile (ACN) in 25mM ammonium bicarbonate and dried in a speed vacuum concentrator. The dried gel pieces were re-swollen using 25mM ammonium bicarbonate (pH 8.0) containing 50 ng trypsin and incubated at 37 C for 24 h. The peptide mixtures were extracted with 50% ACN in 5% formic acid (FA) and dried in a speed vacuum concentrator.
MS analysis
MS was performed as previously described [18] . Briefly, the tryptic-dried peptides were analyzed using the Agilent HPLC-Chip/ TOF MS system with the Agilent 1260 nano-LC system, HPLC Chipcube MS interface and a 6530 QTOF single quadrupole-TOF mass spectrometer (Agilent Technologies, Santa Clara, CA, USA). The dried peptide samples were re-resolved in 2% ACN/0.1% FA and concentrated on a large-capacity HPLC Chip (Agilent Technologies). The HPLC chip incorporated an enrichment column (9 mm, 75 mminner diameter, 160 nL) and a reverse-phase column (15 cm, 75 mm-inner diameter, packed with Zorbax 300SB-C18 5 mm resins). The peptide separation was performed using a 70-min gradient of 3e45% buffer B (buffer A contained 0.1% FA/dry weight, and buffer B contained 90% ACN/0.1% FA/dry weight) at a flow rate of 300 nL/min. The MS and MS/MS data were acquired in positive ion mode and stored in centroid mode. The chip spray voltage was set at 1950 V and maintained under chip conditions. The drying gas temperature was set at 325 C with a flow rate of 3.5 L/min. A medium isolation (4 m/z) window was used for precursor isolation. A collision energy with a slope of 3.7 V/100 Da and an offset of 2.5 V were used for fragmentation. Additionally, while the MS data were acquired over a mass range of 300e3000 m/z, the MS/MS data were acquired over a mass range of 50e2500 m/z. Reference mass correction was performed using a reference mass of 922.0098. Precursors were set in an exclusion list for 0.5 min after two MS/MS spectra. The MS and MS/MS spectra were extracted using the Mass Hunter Qualitative Analysis B.05.00 software (Agilent Technologies) with default parameters. Database searches using the X! Tandem search engine were performed with a peptide mass tolerance of 20 ppm, an MS/MS tolerance of 0.5 Da, and a strict tryptic specificity (cleavage after lysine and arginine) allowing two missed cleavage sites; carbamidomethylation of Cys was set as a fixed modification, whereas oxidation (M) was considered a variable modification.
Protein validation and quantification
The MS database search results were analyzed using the TransProteomic Pipeline (Systems Biology, Seattle, WA, USA), all assigned peptides were validated by PeptideProphet and the results filtered with an error rate of 0.05 (FDR of 5%) [19] . Peptide quantification was performed using the XPRESS modules included in the TransProteomic Pipeline. Protein identification and quantification were validated using ProteinProphet and the result cutoff was set to a protein probability of 80%/error rate of 0.05 (FDR 5%) and a ratio of heavy from fixed to 1. SILAC ratios for proteins were quantified using XPRESS software [19] . The elution profiles of the light and heavy peptides were isolated and quantified based on the area of each peptide peak, and the abundance ratio was calculated based on these areas by XPRESS. Quantitative protein ratios were determined based on the average level of quantified peptides.
Bioinformatics analysis
Functional proteineprotein network analysis was performed using the STRING web-based database Cytoscape plug-in [20] . The subcellular locations of the identified proteins were analyzed using the Uniprot database.
Results and discussion
To investigate the mechanisms associated with the neuroprotective activity of Rg1 in AD, we performed a comparative proteomic analysis of SH-SY5Y cells, which were treated with Rg1 after Ab exposure using nano-LC-MS/MS combined with SILAC. We cultured SH-SY5Y cells in either light SILAC medium containing 12 [18] . Previous studies have shown that fresh and aged Ab 25e35 decreases the cell survival rate based on the results of the MTT reduction assay [21] . Therefore, we used aged Ab 25e35 to induce neuronal toxicity in SH-SY5Y cells. Cells cultured in light medium were exposed to aged Ab 25e35 and then treated with 100mM Rg1 [22] , whereas cells cultured in heavy medium were treated with DMSO after exposure to aged Ab 25e35 (Fig. 1A) .
Three independent SILAC combined with LC-MS/MS experiments were performed. Fig. 1B shows a representative ion chromatogram of the AVIFCLSADKK peptide of destrin, and the monoisotopic peaks in the MS spectra of AVIFCLSADKK showed an expected 1:1 ratio (Fig. 1C) . A total of 2,476 proteins were identified in two different physiological conditions. Of these, 1,149 proteins were common to the three data sets, and 592 proteins were quantified in at least two of the three sets ( Fig. 2A and Table S1 ). Among the quantified proteins, 49 were significantly changed more than 1.5-fold; four proteins were downregulated and 45 proteins were upregulated in Ab-treated SH-SY5Y cells exposed to Rg1 (Fig. 2B and Table 1) .
Next, we analyzed the proteineprotein interaction networks among the proteins that were changed 1.5-fold using the STRING web-based protein database [20] . Proteineprotein interaction clustering was distributed into four cellular locations: mitochondrial proteins (AARS2, ETFB, HSD17B10, COX5A, BCKDK, and TOMM40), actin cytoskeleton proteins (CAP1, CAPZA1, ARPC2, CAPZ2B, and VCL), ribosomal proteins (RPL22, RPL29, PPP2R1A, RPSAP58, ENO3, and RPSA), and regulation of splicing proteins (SRSF1, SNRPD1, SRSF3, SNRNP70, and PRMT1; Fig. 3A) . Interestingly, we have previously reported that Rb1 is linked to the actin cytoskeleton in AD [18] . We noted the identification of mitochondrial proteins because a number of studies have shown that mitochondrial dysfunction is associated with the pathogenesis of AD [3] . Interestingly, the translocase of the outer membrane (TOM) complex has been reported to be the main entrance for most cytoplasmically synthesized mitochondrial proteins, and a decrease in TOMM40 levels causes mitochondrial dysfunction associated with neurodegenerative diseases such as AD [23] . Furthermore, the expression level of TOMM40 was found to be significantly downregulated in blood samples of patients with AD [24, 25] . By contrast, our data showed the opposite results following the treatment of Ab-treated SH-SY5Y cells with Rg1. Fig. 3B shows the relative quantification of TOMM40 expression using an ion chromatogram from MS, which showed that TOMM40 was dramatically increased following treatment with Rg1.
Our previous study showed that mitochondrial proteins were dramatically altered in MPP þ -induced neuronal cells based on a quantitative proteomic analysis. Furthermore, the mitochondrial proteins HSD17B10 and AARS2 containing TOMM40 were dramatically downregulated in response to MPP þ -induced neuronal damage, which is known to be associated with neurodegeneration [19, 26] . However, our results showed that HSD17B10 and AARS2 were noticeably increased by the treatment with Rg1 in Ab-treated SH-SY5Y cells (Table 1 ). These data indicate that Rg1 might have a protective role in the regulation of mitochondrial functions in AD.
To further investigate the functional role of Rg1 in relation to mitochondrial proteins in AD, all of the mitochondrial proteins identified in this study were further explored in the available literature. We found 14 mitochondrial proteins that have been reported to be associated with AD (Table S2) , and we analyzed the proteine protein interaction network among the mitochondrial proteins using the STRING database plug-in Cytoscape. Fig. 3C shows that 14 mitochondrial proteins exhibited a strong interaction network. The thickness of the black connection lines indicates the proteine protein interaction score. Interestingly, VDAC1 has been shown to be significantly increased in AD and transgenic mice [27, 28] , and abnormally high levels of Ab interact with VDAC and interrupt metabolite transport via pore blockade [29] . VDAC1 protein expression was not altered by Rg1 treatment after Ab exposure, in contrast to previous results showing increased levels of VDAC1 in AD. COX5A is the terminal oxidase of the mitochondrial electron transport chain and binds to Ab, resulting in a malfunction of COX5A in cellular energy metabolism in AD and amyloid precursor protein transgenic mice [30] . Interestingly, the interaction between COX5A and TOMM40 is mediated by VDAC1, and the expression of these proteins exhibits a pattern opposite to that observed in Rg1-treated AD (Fig. 3C) . A previous study has shown that NDUFA4 is highly expressed in AD [31] . However, Rg1 treatment decreased NDUFA4. Taken together, our data suggest that Rg1 might play a critical role in regulating the functions of mitochondrial proteins in AD.
In conclusion, numerous studies have been performed to investigate the potential mechanisms of ginsenosides in neuronal diseases such as AD. To explore the neuronal protective mechanism of Rg1 in AD, we performed a global proteomic analysis using SILAC together with LC-MS/MS. In total, 1,149 proteins were identified in the three replicated experiments. A total of 45 proteins showed significant alterations in response to Rg1 treatment in Ab-pretreated cells. Our data showed that these proteins were associated with mitochondrial proteins, actin cytoskeleton proteins, ribosomal proteins, and proteins that regulate splicing. In particular, the results showed that mitochondrial proteins containing HSD17B10, AARS2, TOMM40, VDAC1, COX5A, and NDUFA4 might be related to the protective mechanisms of Rg1 in AD. Additional studies are needed to investigate the detailed molecular mechanisms that link Rg1 to these proteins in AD.
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